Screener
Phathom Pharmaceuticals, Inc. PHAT Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324867
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current portion of revenue interest financing liability | 37,283 | 27,249 |
| Other current liabilities | — | 7,500 |
| Total current liabilities | 153,777 | 132,044 |
| Long-term debt, net of discount | 164,587 | 209,087 |
| Revenue interest financing liability | 347,629 | 350,122 |
| Operating lease liabilities | 1,855 | 2,065 |
| Other long-term liabilities | 3,500 | 4,000 |
| Total liabilities | 671,348 | 697,318 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Phathom Pharmaceuticals, Inc.'s long-term debt?
- Phathom Pharmaceuticals, Inc. (PHAT) reported long-term debt of $164.59M in Q2 2026.
- How has Phathom Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s long-term debt decreased by 19.8% year-over-year, from $205.14M to $164.59M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s long-term debt has grown at a 39.5% compound annual growth rate (CAGR), from $39.63M to $209.09M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Phathom Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude